Evidence map›Paper›PMID 24684781›Full record

ReviewMayo Clinic proceedings2014

Contemporary strategies in the diagnosis and management of heart failure.

Shannon M Dunlay, Naveen L Pereira, Sudhir S Kushwaha

Abstract readReview
In one paragraph

Review in Mayo Clinic proceedings, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Incidence of Preclinical Heart Failure in a Community Population.Journal of the American Heart Association · 2022
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shannon M DunlayDivision of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN; Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, MN. Electronic address: Dunlay.Shannon@mayo.edu.
Naveen L PereiraDivision of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
Sudhir S KushwahaDivision of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN.

Funding

End of Life Preferences and Healthcare Resource Use in Heart Failure PatientsK23HL116643 · NHLBI · MAYO CLINIC ROCHESTER · PI DUNLAY, SHANNON MARIE · 2013 to 2017
$739k
NHLBI NIH HHS 1K23 HL116643NHLBI NIH HHS K23 HL116643
6 · The paper itself

Abstract

Heart failure (HF) is an important public health problem, and strategies are needed to improve outcomes and decrease health care resource utilization and costs. Its prevalence has increased as the population ages, and HF continues to be associated with a high mortality rate and frequent need for hospitalization. The total cost of care for patients with HF was $30.7 billion in 2012, and it is estimated to more than double to $69.8 billion by 2030. Given this reality, there has been recent investigation into ways of identifying and preventing HF in patients at risk (stage A HF) and those with cardiac structural and functional abnormalities but no clinical HF symptoms (stage B). For patients who have symptoms of HF (stage C), there has been important research into the most effective ways to decongest patients hospitalized with acute decompensated HF and prevent future hospital readmissions. Successful strategies to treat patients with HF and preserved ejection fraction, which has increased in prevalence, continue to be sought. We are in the midst of a rapid evolution in our ability to care for patients with end-stage HF (stage D) because of the introduction of and improvements in mechanical circulatory support. Left ventricular assist devices used as destination therapy offer an important therapeutic option to patients who do not qualify for heart transplant because of advanced age or excessive comorbidity. This review provides a thorough update on contemporary strategies in the diagnosis and management of HF by stage (A to D) that have emerged during the past several years.

Indexed as

AgedAged, 80 and overAge FactorsCenters for Medicare and Medicaid Services, U.S.ComorbidityCost ControlDisease ManagementFemaleHeart FailureHumansMaleMiddle AgedPatient ReadmissionPrevalenceQuality Assurance, Health CareQuality Indicators, Health Care

Identifiers

PMID24684781
PMCPMC4922303

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.